title: Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination.
abstract: Fixed-dose combination (FDC) products represent a widely accepted approach to type 2 diabetes treatment, given that monotherapies sometimes fail to meet the treatment targets - obtaining a sustained reduction in micro- and macrovascular complications. Saxagliptin (SAXA)/metformin (MET) FDC tablets can be used either alone or in combination with glyburide, thiazolidinediones, or insulin. It has been proven that the SAXA/MET combination leads to a significant improvement in glycemic control compared to placebo in patients with type 2 diabetes that is inadequately controlled with MET alone. In addition, this FDC has been proven to be safe for people with diabetes mellitus and established cardiovascular disease, elderly patients, and patients with impaired renal function (>30 mL/minute), with dosage modification. Patient compliance, adherence, and persistence to the therapeutic regimen has been shown to be very good, while the titration of each compound according to the patient's profile is easy, given the availability of different formulations. The SAXA/MET FDC is a patient-friendly, dosage-flexible, and hypoglycemia-safe regimen with very few adverse events and a neutral or even favorable effect on body weight. It achieves significant glycosylated hemoglobin A1c reduction helping the patient to achieve his/her individual glycemic goals.
authors.affiliation: 1st Department of Propaedeutic and Internal Medicine, Athens University Medical School,Laiko General Hospital, Athens, Greece.
authors.forename: George S
authors.initials: GS
authors.lastname: Panagoulias
authors.affiliation: Salamis Naval Hospital, Athens, Greece ; DiabetesDivision, Iatriko Paleou Falirou Medical Center, Athens, Greece.
authors.forename: John
authors.initials: J
authors.lastname: Doupis
keywords: DPP-4 inhibitors; FDC products; fixed-dose combination products; metformin; saxagliptin